Wehler, Elizabeth http://orcid.org/0000-0001-5059-882X
Boytsov, Natalie
Nicolay, Claudia
Herrera-Restrepo, Oscar
Kowal, Stacey
Funding for this research was provided by:
Eli Lilly and Company
Article History
First Online: 27 August 2019
Change Date: 12 November 2019
Change Type: Correction
Change Details: Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article.
Compliance with Ethical Standards
:
: This study was funded by Eli Lilly and Company. This study is available via Springer Open Choice, with the fee paid for by Eli Lilly and Company.
: Elizabeth Wehler, Oscar Herrera-Restrepo, and Stacey Kowal are employees of IQVIA who were hired by Eli Lilly and Company to conduct the analysis. Natalie Boytsov and Claudia Nicolay are employees and shareholders of Eli Lilly and Company.
: EW, SK, and NB developed the budget impact model along with number needed to treat and cost per responder calculations. CN developed the systematic literature review and network meta-analysis. OH-R collected data, performed computations, and consolidated results. All authors discussed the results and contributed to the final manuscript writing and revisions.
: The datasets generated and/or analyzed during the current study are not publicly available as they contain proprietary data but are available from the corresponding author on reasonable request.